Evidence map›Paper›PMID 37616559›Full record

ArticleBlood2023

Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress.

Ashley F Melnick, Carea Mullin, Karena Lin, Anna C McCarter, Shannon Liang, Yiran E Liu, Qing Wang, Nicole A Jerome, Elizabeth Choe, Nicholas Kunnath and 10 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. ETS1 Function in Leukemia and Lymphoma.Advances in experimental medicine and biology · 2024
    Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Ashley F MelnickCellular and Molecular Biology Program, University of Michigan School of Medicine, Ann Arbor, MI.
Carea MullinDivision of Hematology-Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI.
Karena LinCellular and Molecular Biology Program, University of Michigan School of Medicine, Ann Arbor, MI.
Anna C McCarterCellular and Molecular Biology Program, University of Michigan School of Medicine, Ann Arbor, MI.ORCID 0000-0003-3828-9797
Shannon LiangDepartment of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, CA.
Yiran E LiuCancer Biology Program, Stanford University, Stanford, CA.ORCID 0000-0001-7964-712X
Qing WangDivision of Hematology-Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI.
Nicole A JeromeCancer Biology Program, University of Michigan School of Medicine, Ann Arbor, MI.ORCID 0009-0001-9251-0408
Elizabeth ChoeDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI.
Nicholas KunnathCenter for Healthcare Outcomes and Policy, University of Michigan School of Medicine, Ann Arbor, MI.ORCID 0000-0001-5589-6041
Geethika BodanapuSchool of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA.
Fatema AkterDepartment of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, CA.ORCID 0009-0004-6080-8164
Brian MagnusonMichigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, MI.
Surinder KumarDepartment of Pathology and Laboratory Medicine and Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL.ORCID 0000-0003-0287-5612
David B LombardDepartment of Pathology and Laboratory Medicine and Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL.ORCID 0000-0002-4292-0185
Andrew G MunteanCellular and Molecular Biology Program, University of Michigan School of Medicine, Ann Arbor, MI.
Mats LjungmanCellular and Molecular Biology Program, University of Michigan School of Medicine, Ann Arbor, MI.ORCID 0000-0003-1553-6695
JoAnn SekiguchiCancer Biology Program, University of Michigan School of Medicine, Ann Arbor, MI.ORCID 0000-0002-7178-4258
Russell J H RyanCellular and Molecular Biology Program, University of Michigan School of Medicine, Ann Arbor, MI.ORCID 0000-0001-8174-3962
Mark Y ChiangCellular and Molecular Biology Program, University of Michigan School of Medicine, Ann Arbor, MI.
University of Michigan · USStanford Medicine · USUniversity of Miami · USBoston University · USStanford University · US

Funding

MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
CELLULAR AND MOLECULAR BIOLOGY AT MICHIGANT32GM007315 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PUTHENVEEDU, MANOJKUMAR A · 1985 to 2021
$12.8M
Cellular and Molecular Biology at MichiganT32GM145470 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI John Chadwick Brenner · 2022 to 2026
$4.1M
Regulation of one carbon metabolism and epigenetics by SIRT5R01GM101171 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOMBARD, DAVID BENNER · 2012 to 2021
$2.6M
Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell developmentR01AI136941 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHIANG, MARK Y · 2019 to 2023
$2.5M
The MRN complex in Lymphocyte Development and Genome StabilityR01HL153068 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SEKIGUCHI, JOANN · 2021 to 2023
$2.0M
The role of the PAFc subunit Cdc73 in normal hematopoiesis and transformationR01HL136420 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MUNTEAN, ANDREW GEORGE · 2018 to 2022
$1.9M
ETS1-dependent combinatorial control of oncogenic transcription in Notch-activated T-ALLR01CA276117 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARK Y CHIANG · 2023 to 2026
$1.8M
Investigating the Role of Cdc73 in T-cell Acute Lymphoblastic Leukemia (T-ALL)F31CA260929 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MELNICK, ASHLEY · 2021 to 2023
$92k
NCI NIH HHS F31 CA260929NCI NIH HHS R01 CA276117NHLBI NIH HHS R01 HL136420NHLBI NIH HHS R01 HL153068NIAID NIH HHS R01 AI136941NIGMS NIH HHS R01 GM101171NIGMS NIH HHS T32 GM007315NIGMS NIH HHS T32 GM007863NIGMS NIH HHS T32 GM145470
6 · The paper itself

Abstract

abstractActivated Notch signaling is highly prevalent in T-cell acute lymphoblastic leukemia (T-ALL), but pan-Notch inhibitors showed excessive toxicity in clinical trials. To find alternative ways to target Notch signals, we investigated cell division cycle 73 (Cdc73), which is a Notch cofactor and key component of the RNA polymerase-associated transcriptional machinery, an emerging target in T-ALL. Although we confirmed previous work that CDC73 interacts with NOTCH1, we also found that the interaction in T-ALL was context-dependent and facilitated by the transcription factor ETS1. Using mouse models, we showed that Cdc73 is important for Notch-induced T-cell development and T-ALL maintenance. Mechanistically, chromatin and nascent gene expression profiling showed that Cdc73 intersects with Ets1 and Notch at chromatin within enhancers to activate expression of known T-ALL oncogenes through its enhancer functions. Cdc73 also intersects with these factors within promoters to activate transcription of genes that are important for DNA repair and oxidative phosphorylation through its gene body functions. Consistently, Cdc73 deletion induced DNA damage and apoptosis and impaired mitochondrial function. The CDC73-induced DNA repair expression program co-opted by NOTCH1 is more highly expressed in T-ALL than in any other cancer. These data suggest that Cdc73 might induce a gene expression program that was eventually intersected and hijacked by oncogenic Notch to augment proliferation and mitigate the genotoxic and metabolic stresses of elevated Notch signaling. Our report supports studying factors such as CDC73 that intersect with Notch to derive a basic scientific understanding on how to combat Notch-dependent cancers without directly targeting the Notch complex.

Indexed as

5'-NucleotidaseLeukemia, T-CellPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAnimalsCell Line, TumorChromatinDNA DamageMiceMitochondriaReceptor, Notch1Transcription Factors5'-NucleotidaseChromatinReceptor, Notch1Transcription Factors

Identifiers

PMID37616559
PMCPMC10733839
OpenAlexW4386118819

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.